Moderna COVID-19 vaccine: Continued monitoring

Moderna COVID-19 vaccine: Continued monitoring At the time of authorization, no major safety concerns have been reported in the available data submitted to Health Canada. We are carefully monitoring the post-market (after authorization) safety and effectiveness of authorized COVID-19 vaccines. As part of our commitment to keep Canadians informed, we are publishing information about adverse events following immunization (AEFI). 2021-07-29 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyCOVID-19pandemicModerna COVID-19 vaccineauthorized COVID-19 vaccinesurgent public health needsmarket authorizationcontinued monitoringpost-market safetyeffectivenessadverse events following immunizationAEFI Moderna COVID-19 vaccine: Continued monitoringHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/moderna/monitoring.html Moderna COVID-19 vaccine: Continued monitoringHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/covid19-industrie/medicaments-vaccins-traitements/vaccins/moderna/surveillance.html

At the time of authorization, no major safety concerns have been reported in the available data submitted to Health Canada. We are carefully monitoring the post-market (after authorization) safety and effectiveness of authorized COVID-19 vaccines. As part of our commitment to keep Canadians informed, we are publishing information about adverse events following immunization (AEFI).

Data and Resources

Similar records